CareDx raises 2026 revenue outlook to $520M-$530M as it plans AlloHeme launch in Q1 2027 (NASDAQ:CDNA)
· seekingalpha.com
CareDx Q3 2026 earnings: revenue jumps 39%, guidance rises, and AlloHeme launch stays on track.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...